Closing Bell: Sensex, Nifty End Flat After FM Budget Speech, Maruti Suzuki Gains 4.40%

Indian equity indices ended with decline in the volatile session on Thursday after Finance Minister Nirmala Sitharaman presented the inline Interim Budget with no big announcements. At close, the Sensex witnessed decline of 106.81 points or 0.15% at 71,645.30, and the Nifty was down 28.20 points or 0.13% at 21,697.50.

Meanwhile, Paytm shares hit 20% lower circuit today after the Reserve Bank of India (RBI) on Wednesday ordered Paytm Payments Bank to stop accepting fresh deposits in its accounts or popular wallets after February 29, 2024. Current market price of Paytm shares on BSE is Rs 608.80 apiece.

Indian stock indices kicked off on a positive note on February 1, with Nifty crossing the 21,750 mark ahead of the Interim Budget. The Sensex witnessed a gain of 63.63 points or 0.09%, reaching 71,815.74, while the Nifty experienced a rise of 24.20 points or 0.11%, reaching 21,749.90. Among the stocks in play, 1763 showed advancement, 664 witnessed a decline, and 89 remained unchanged.

Major gainers on the Nifty included Eicher Motors, BPCL, Tata Motors, M&M, and Maruti Suzuki, whereas the losers featured Wipro, L&T, LTIMindtree, Britannia, and Nestle.

The Nifty 50 witnessed a rollercoaster ride at the beginning of the February F&O series. After a robust start, the index stumbled mid-week, only to regain momentum and close near the 21,750 mark, leaving traders on edge.

All eyes are now on Finance Minister Nirmala Sitharaman as she gears up to present the Union Budget on Thursday. While the market anticipates a Vote on Account or an interim budget, expectations are rife for a clear direction on policy and the road ahead, making it a crucial moment for investors.

The Nifty Bank often considered the weaker sibling to the Nifty, showcased unexpected strength on Wednesday during its options contracts' weekly expiry. Although still 5.5% away from its record high, the index closed within striking distance of the 46,000 mark, offering a glimmer of hope to the bulls.

As the market gears up for Thursday's trading session, here are the stocks in the spotlight:

Paytm: The Reserve Bank of India (RBI) has directed Paytm Payments Bank to halt the onboarding of new customers due to observed deficiencies in technology and customer redressal mechanisms. Paytm faces potential challenges, estimating an impact of Rs 300 crore to Rs 500 crore on its annual EBITDA in the worst-case scenario.

Dixon Technologies: Despite doubling year-on-year revenue, Dixon Technologies' net profit of Rs 97 crore falls short of estimates. The mobile business, contributing two-thirds of the revenue, sees a decline on a sequential basis.

Godrej Consumer Products: Solid operational performance leads to sharp margin expansion for Godrej Consumer Products, with consolidated revenue surpassing expectations. The LatAm currency impact weakens revenue, but domestic organic volume growth and EBITDA margin outperform market estimates.

Shree Cement: In-line sales volumes and lower costs contribute to Shree Cement's better-than-expected EBITDA. The company also announces an interim dividend of Rs 50 per share.

JSPL: Jindal Steel and Power Limited reported a December quarter net profit of Rs 1,928 crore, significantly surpassing estimates. The benefits from captive thermal coal mines in India start materializing, resulting in lower raw material costs and a better EBITDA.

Mankind Pharma: Mankind Pharma sees a robust financial performance with a 25% increase in revenue, a 39% rise in EBITDA, and a 55% surge in net profit. The company maintains a strong net cash balance of Rs 2,756 crore.

Cochin Shipyard: Secures a Rs 500 crore order from a European client for the design and construction of a hybrid service operation vessel (SOV), to be delivered in 2026.

Divgi TorqTransfer Systems: Wins orders worth Rs 212.1 crore from two North American automotive transmission manufacturers over a five-year period, contributing to the expansion of the product portfolio.

Glenmark Pharma: Collaborates with Pfizer to launch Abrocitinib in India, a drug approved for the treatment of Atopic Dermatitis.

Amidst these market dynamics, global cues present a mixed scenario. Asian markets opened with variations, responding to Fed Chair Jerome Powell's announcement of no rate cut in March. The US markets experienced a decline, with the S&P 500 falling the most since September, setting the stage for a potentially muted start for the Indian market as indicated by GIFT Nifty against Nifty Futures Wednesday close.

LIVE Feed

More From GoodReturns

Notifications
Settings
Clear Notifications
Notifications
Use the toggle to switch on notifications
  • Block for 8 hours
  • Block for 12 hours
  • Block for 24 hours
  • Don't block
Gender
Select your Gender
  • Male
  • Female
  • Others
Age
Select your Age Range
  • Under 18
  • 18 to 25
  • 26 to 35
  • 36 to 45
  • 45 to 55
  • 55+